Our top pick for
Xtant Medical Holdings, Inc is a medical devices business based in the US. Xtant Medical shares (XTNT) are listed on the NYSE MKT and all prices are listed in US Dollars. Xtant Medical employs 110 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$0.63 - $4.90|
|50-day moving average||$2.47|
|200-day moving average||$1.76|
|Wall St. target price||$1.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.90|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Xtant Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xtant Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Xtant Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.9 million.
The EBITDA is a measure of a Xtant Medical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$53.3 million|
|Operating margin TTM||1.59%|
|Gross profit TTM||$34.4 million|
|Return on assets TTM||1.25%|
|Return on equity TTM||0%|
|Market capitalisation||$173.4 million|
TTM: trailing 12 months
There are currently 60,127 Xtant Medical shares held short by investors – that's known as Xtant Medical's "short interest". This figure is 267.2% up from 16,376 last month.
There are a few different ways that this level of interest in shorting Xtant Medical shares can be evaluated.
Xtant Medical's "short interest ratio" (SIR) is the quantity of Xtant Medical shares currently shorted divided by the average quantity of Xtant Medical shares traded daily (recently around 1.0 million). Xtant Medical's SIR currently stands at 0.06. In other words for every 100,000 Xtant Medical shares traded daily on the market, roughly 60 shares are currently held short.
However Xtant Medical's short interest can also be evaluated against the total number of Xtant Medical shares, or, against the total number of tradable Xtant Medical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xtant Medical's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Xtant Medical shares in existence, roughly 0 shares are currently held short) or 0.0045% of the tradable shares (for every 100,000 tradable Xtant Medical shares, roughly 5 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xtant Medical.
Find out more about how you can short Xtant Medical stock.
We're not expecting Xtant Medical to pay a dividend over the next 12 months.
Xtant Medical's shares were split on a 1:12 basis on 13 February 2018. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xtant Medical shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Xtant Medical shares which in turn could have impacted Xtant Medical's share price.
Over the last 12 months, Xtant Medical's shares have ranged in value from as little as $0.629 up to $4.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Xtant Medical's is 1.5808. This would suggest that Xtant Medical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as used in conjunction with a hardware plate system. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous Fusion System; Silex Sacroiliac joint fusion system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.